Navigation Links
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009.

NXL104, Novexel's broad spectrum class A and C beta-lactamase inhibitor, is the subject of one poster. Novexel is currently conducting two Phase II clinical trials in patients with complicated urinary tract infections and complicated intra-abdominal infections with NXL104 in combination with ceftazidime. The poster provides in vitro data showing that a ceftazidime/NXL104 combination is rapidly bactericidal against a range of beta-lactamase-producing strains of Enterobacteriaceae, including E. coli, and Klebsiella. Data presented also showed that one of the most important factors affecting the pharmacodynamics of the combination is maintaining a critical concentration of the inhibitor (NXL104) to suppress beta-lactamase activity. (Poster P 1463).

NXL103, a novel oral streptogramin antibiotic, is the subject of three posters at the ECCMID conference. Novexel has recently completed a successful Phase II study with NXL103 in patients with community acquired pneumonia. The first of the three posters provides in vitro data showing that NXL103 was active against methicillin resistant Staphylococcus aureus (MRSA) and organisms responsible for lower respiratory tract infections, including Streptococcus pneumoniae and Haemophilus influenzae , (Poster P 1393). The second poster contains in vivo data demonstrating that, following oral administration, NXL103 was able to kill intracellular drug-resistant and non-drug-resistant strains of Staphylococcus aureus in infected macrophages, (Poster P 1025). The final poster shows that NXL103 was active in vitro against both community-acquired and hospital-acquired strains of MRSA. The poster also showed that NXL103 was subject to a low spontaneous frequency of resistance (Poster P 1102).

It is Novexel's intention to seek partners for both the NXL104/ceftazidime combination and NXL103 in certain geographies.

All four posters will be available for download from Novexel's web site ( shortly after the close of the ECCMID conference.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated US$17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel's partner, Forest Laboratories (NYSE: FRX), solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

    [1] Source: IMS Health, MIDAS, 2006-2008

    For further information please contact:
    Gordon Waldron, CFO

    Citigate Dewe Rogerson
    Amber Bielecka/David Dible/Nina Enegren
    Tel.: +44-207-638-95-71

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
2. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
5. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Post Your Comments:
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):